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In doing liver transplantation, it is important to know the effect of immunosuppressive agents
on hepatic regeneration. In many such patients, livers are transplanted that are not the ideal
size for a particular recipient. Accommodation of these organs to recipient size depends on
poorly understood growth homeostasis which conceivably could be altered by the
immunosuppressive agents. In fact, it has been reported that the regeneration response is
inhibited by azathioprine and adrenal cortical steroids. 1,2
CyA AND REGENERATION
Largely because of such concerns, Makowka et al3 tested hepatic generation after partial
hepatectomy in rats treated with CyA and reported that the regeneration response was actually
greater than normal. This finding has been confirmed by several investigators.4–6
FK 506 AND REGENERATION
More recently, we have demonstrated an even more dramatic augmentation of hepatic
regeneration by FK 506. CyA and FK 506 have completely different molecular structures (Fig
1), but they have in common the relatively specific inhibition of the T cell component of the
immune system.7,8 Because of this similar mechanism. we have suggested that hepatic
regeneration may be subject to immune modulation.6
The Immune modulation hypothesis was supported by the data summarized in Fig 2. In essence,
the increase in DNA and mitotic activity which is characteristic of a 70% hepatic resection in
rats was increased significantly with CyA and nearly doubled when FK 506 was administered
for 3 days preoperatively and for a final time just after completing the hepatic resection.
IN VITRO MECHANISMS
What was the explanation for these curious results? The first step was to establish pure
hepatocyte cultures9 and to determine if the resting rate of mitoses was altered by the direct
addition of CyA or FK 506 to the medium. A wide range of doses of both drugs was completely
without effect (Fig 3).
Hepatocyte cultures were now used for additional experiments under two different conditions
that are known to increase the basal rate of mitoses. In the first experiment, epidermal growth
factor was added to the hepatocyte culture which, as expected.10 increased the basal mitotic
rate approximately 10-fold. The addition of CyA and FK 506 had no further effect (Fig 3).
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In the second experiment, normal rat serum, which in tissue culture systems is mitogenic in
low doses.9 was added to the hepatocyte culture in graded quantities (Table 1). The expected
increase in mitoses was seen at first with an inhibition of this effect as larger volumes of normal
rat serum were added (Table 1). As in the first experiment, there was no augmentation effect
with CyA on FK 506.
From this we concluded that neither CyA nor FK 506 had a direct effect on hepatocyte mitoses,
no matter whether the mitotic index was at a resting or heightened level at the time of addition
of the drug to the medium.
In contrast, the serum from animals treated for 4 days with therapeutic doses of CyA and FK
506 had a pronounced effect on hepatocyte cultures (Table 1). These sera caused an increase
in mitosis far exceeding that seen with comparable amounts of normal rat serum. The
stimulatory potency of the rat serum was greater if the serum donors were treated with FK 506
than if therapy was with CyA.
ARE THESE GROWTH EFFECTS LIVER SPECIFIC?
We questioned whether CyA and FK 506 altered the regeneration of other organ systems. To
test this possibility, DNA synthesis was measured in kidneys before and after right
nephrectomy. The basal level of DNA synthesis was essentially doubled in the contralateral
kidney after right nephrectomy, but this was not further increased by the treatment with FK
506 that enhanced liver regeneration (Table 2).
With resection of 50% of the small bowel, DNA synthesis in the residual small bowel tripled,
as has been described by others.11 This powerful regeneration response was neither increased
or decreased by treatment of these animals with FK 506 (Table 2).
DISCUSSION AND CONCLUSIONS
These observations could have a deeper biologic significance than those practical questions
which prompted us to begin these studies. It remains possible that the immune system has a
“braking” effect on hepatocyte cell mitosis, and that this is unmasked by powerful T cell-
specific immunosuppression. From the work presented here, it is probable that this control is
at least relatively liver-specific: at least it could not be identified in regenerating kidney or
intestine. The fact that CyA and FK 506 did not have a direct action on cultured hepatocytes.
but that the serum of immunosuppressed animals was stimulatory to these same cell cultures,
suggests that some circulating substance is induced by CyA and FK 506. CyA and FK 506 act
by inhibiting IL2 production and binding. 7,8 It is conceivable that by inhibition of this second
signal, both drugs could interrupt the secretion of liver regulatory factors, either by as yet
unknown immune mechanisms or, possibly, by pathways that are not directly connected with
the immune system.
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Fig 1.
Structural formulas of FK 506 and CyA.
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Fig 2.
[3H]-thymidine incorporation and percentage of mitosis in normal and 70% hepatectomized
rats treated or not treated with FK 506 and CyA. Control and immunosuppressive drug-treated
animals were given intramuscular injections of vehicle and CyA and FK 506, 1 mg/kg body
weight, respectively, for 3 days before surgery and again just after completing hepatic resection.
The values represented by the bars are the means from at least 15 rats ± SD. *Significantly
different from 70% hepatectomized rats (P< 0.05). **Significantly different from 70%
hepatectomized rats (P < 0.01) and CyA-treated 70% hepatectomized rats (P < 0.05).
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Fig 3.
Effect of different doses of FK 506 and CyA on DNA synthesis in hepatocytes cultured in
presence or not of epidermal growth factor (EGF). (Solid line, FK 506; broken line, CyA.)
Hepatocytes were isolated as previously described.9 They were plated at a density of 1.5 ×
105 cell/dish in 1.5 ml of minimum essential medium (MEM) + 5% fetal calf serum + insulin
(10−7 mol/L) and maintained at 37°C in a 5% CO2 atmosphere. Following a 3-hour attachment
period, the medium was substituted with 1.5 ml of fresh MEM and insulin with or without EGF
(10 mg/ml). DNA content and [3H]-thymidine incorporation were determined as previously
described.6 When added to the incubation medium, FK 506 and CyA vehicles were used at
concentrations <0.2 μl/ml, which did not affect hepatocyte proliferation (data not shown). The
values reported represent the means of five experiments ± SD.
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Table 2
[3H]-Thymidine Incorporation In Kidney and Small intestine From Normal. Nephrectomized, or Small Intestine-
Resected Rats Treated or Not With FK 506
Group No. Treatment (IM) Surgery [3H]-Thymidine Incorporation (cpm/mg DNA)
1 Vehicle No 2,930 ± 650
2 Vehicle Unilateral nephrectomy 5,012 ± 559*
3 FK 506 Unilateral nephrectomy 4,971 ± 702*
4 Vehicle No 13,420 ± 16,216
5 Vehicle 40% small intestine resection 73,711 ± 17,071†
6 FK 506 40% small intestine resection 79,823 ± 30,973†
Note: Surgical procedures have been described elsewhere.11 The treatment follows the same scheme used for the partial) hepatectomized animals
described in Fig 2. The values reported are the means from five rats ± SD.
*
Significantly different from thymidine incorporation in kidneys from non-operated animals (P < 0.05).
†
Significantly different from thymidine incorporation in the small intestine from non-operated animals (P < 0.05).
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